DBC-664 for Cancer

This trial tests a new treatment called DBC-664 to determine its safety and effectiveness for individuals with certain advanced cancers, including endometrial and ovarian cancer. In the first phase, researchers will determine the appropriate dose of DBC-664. In the second phase, they will study its effects on tumors. Suitable participants have advanced cancer that cannot be surgically removed and can be measured with imaging tests. As a Phase 1 trial, participants will be among the first to receive this treatment, aiding researchers in understanding its effects in humans.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

A previous study tested DBC-664 on adults with advanced solid tumors to assess its safety and efficacy. Participants generally tolerated the treatment well, and researchers reported no major safety issues. However, since this marks the first human trial of DBC-664, all potential side effects remain under close observation. This study is in an early phase, so researchers primarily focus on ensuring the treatment's safety. Participants will help researchers understand how well patients with cancer can handle DBC-664.¹²³⁴⁵

Researchers are excited about DBC-664 for cancer because it offers a novel approach compared to traditional treatments like chemotherapy and radiation. Unlike these standard treatments, which often target rapidly dividing cells indiscriminately, DBC-664 specifically targets cancer cells, potentially minimizing harm to healthy cells. This targeted mechanism could lead to fewer side effects and improved patient outcomes. Additionally, DBC-664's ability to precisely attack tumor cells may enhance its effectiveness, making it a promising candidate in cancer therapy.

Research has shown that DBC-664 exhibits early signs of tumor-fighting potential. In one study, about 45% of patients responded well to the treatment, with some experiencing complete tumor disappearance. This trial will evaluate DBC-664 in two parts: Part 1 will determine the recommended dose for expansion, and Part 2 will confirm the safety and anti-tumor activity at that dose. DBC-664 might help shrink or control tumors, offering hope for treating cancers like endometrial and ovarian cancer. Although these results are promising, DBC-664 remains in the early stages of research, and further studies are needed to fully understand its efficacy.⁶⁷⁸⁹¹⁰